Patent intelligence · US
US 7169801
Histone deacetylase inhibitors
Histone deacetylase inhibitors
Patent details — US 7169801
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 30, 2007
- Expiration
- Jan 25, 2027
- Applicant
- Takeda San Diego, Inc.
- Claims
- 67
- CPC classes
- A61P, A61P1/04, A61P15/00, A61P17/02
Quick answer
US 7169801 (Histone deacetylase inhibitors) is held by Takeda San Diego, Inc.. Status: granted. Granted Jan 30, 2007. Expires Jan 25, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Takeda San Diego, Inc.
- Grant date
- Expiration
- Claims
- 67
- CPC classes
- A61P, A61P1/04, A61P15/00, A61P17/02, A61P17/06, A61P19/02
More from Takeda San Diego, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 7169801?
US 7169801 (Histone deacetylase inhibitors) is held by Takeda San Diego, Inc.. Status: granted. Granted Jan 30, 2007. Expires Jan 25, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7169801?
Takeda San Diego, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 7169801 expire?
Our index shows an expiration date of Jan 25, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.